Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

  • On October 22, 2013 Shire announced that it had decided to discontinue the construction of its new manufacturing facility in San Diego. Shire will continue to manufacture DERMAGRAFT in its existing facility in La Jolla, and Shire's ability to meet expected future demand for DERMAGRAFT is not impacted by this decision.  Shire is currently assessing possible disposal opportunities in relation to this facility.

  • Share Buy-Back Program

    • In Q4 2012 Shire commenced a share buy-back program, for the purpose of returning funds to shareholders, of up to $500 million, through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying American Depositary Receipts. As of October 22, 2013 Shire had made on-market repurchases totaling 9,807,835 Ordinary Shares at a cost of $299 million (excluding transaction costs).

    BOARD AND COMMITTEE CHANGES

    • On October 23, 2013 Shire announced that Dominic Blakemore will join the Shire Board of Directors effective January 1, 2014.  On joining the Board, Dominic will become a member of the Shire Audit, Compliance & Risk Committee. Dominic's career experience includes finance and strategy roles with global corporations.  He is currently Group Finance Director of Compass Group plc.

    ADDITIONAL INFORMATION

    The following additional information is included in this press release:

    Page Overview of Third Quarter 2013 Financial Results 6 Financial Information 10 Non GAAP Reconciliation 19 Notes to Editors 23 Safe Harbor Statement 24 Explanation of Non GAAP Measures 24 Trade Marks 25

     

    Dial in details for the live conference call  for investors at 14:00 BST / 09:00 ED
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... of circulating tumor cells (CTCs) in a mouse model ... in several groups of CTCs, including significant differences from ... to generate metastases. In their study reported in ... investigators from the Massachusetts General Hospital (MGH) Cancer Center ... unexpected factors that may prove to be targets for ...
    (Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
    (Date:9/22/2014)... (PRWEB) September 22, 2014 Lawrence ... President John DeGioia on Friday renewed their institutional ... an additional five years to expand the collaborative ... nonproliferation and global climate, energy and environmental sciences. ... an MOU originally signed in December 2009 and ...
    (Date:9/22/2014)... Sept. 22, 2014 US demand to rise ... specialty biocides is forecast to rise 3.9 percent per ... demand is projected to increase 1.3 percent per year ... strong rebound in construction expenditures will support demand for ... markets, while growth in consumer spending and manufacturing output ...
    Breaking Biology Technology:Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2US Biocides Market 2US Biocides Market 3
    ... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
    ... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
    ... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
    Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
    (Date:9/21/2014)... new strains of bacteria have emerged that resist even ... drug-resistant forms of tuberculosis and staphylococcus, infect more than ... Despite the urgent need for new treatments, scientists have ... past decade. , MIT engineers have now turned a ... system that can disable any target gene, they have ...
    (Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
    (Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
    Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
    ... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
    ... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
    ... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
    Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
    Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
    Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
    Weinreb Linker...
    Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
    Biology Products: